Hann M.M.,Medicines Research Center |
Hann M.M.,Society for Medicines Research |
Alderton W.,Abcodia Ltd |
Davenport R.,C4X Discovery |
Drugs of the Future | Year: 2017
This symposium featured an international lineup of speakers presenting on the discovery and clinical development of novel therapeutic agents. The presentations described a variety of mechanistic approaches including small molecules, monoclonal antibodies and a drug repurposing and covered therapeutics areas from oncology, anti-infectives and inflammation to anemia. The program also included the 2016 Society forMedicines Research Award Lecture given by Dr. Francis Cuss,Executive Vice President & CSO R&D, Bristol-Myers Squibb,on the discovery, development and delivery of Opdivo(nivolumab), which is a fully human anti-programmed celldeath protein 1 (PD-1) antibody. The meeting was held at the National Heart and Lung Institute, Kensington, London, U.K.and was organized by the authors of this report. © 2017 Clarivate Analytics.
News Article | May 3, 2017
Summary Nicotine addiction also called tobacco dependence is an addiction to tobacco products caused by the drug nicotine. Predisposing factors include age, depression, schizophrenia, post-traumatic stress disorder and alcoholism. Person experiences withdrawal symptoms at cessation of using, such as shaky hands, sweating, irritability, or rapid heart rate. Treatment includes nicotine replacement therapy (NRT). Report Highlights Pharmaceutical and Healthcare latest pipeline guide Nicotine Addiction – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Nicotine Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Nicotine Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Nicotine Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 11 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively. Nicotine Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Nicotine Addiction (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Nicotine Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Nicotine Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Nicotine Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Nicotine Addiction (Central Nervous System) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Nicotine Addiction (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Nicotine Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. Table of Content: Key Points List of Tables List of Figures Introduction Nicotine Addiction - Overview Nicotine Addiction - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Nicotine Addiction - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Nicotine Addiction - Companies Involved in Therapeutics Development Addex Therapeutics Ltd Astraea Therapeutics LLC C4X Discovery Holdings PLC Chronos Therapeutics Ltd CV Sciences Inc Hager Biosciences LLC Heptares Therapeutics Ltd …Continued For more information, please visit http://www.wiseguyreports.com
News Article | November 10, 2016
ReportsnReports.com adds "Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2016" to its store providing comprehensive information on the therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Complete report on H2 2016 pipeline review of Chronic Obstructive Pulmonary Disease (COPD) with 172 market data tables and 16 figures, spread across 577 pages is available at http://www.reportsnreports.com/reports/743409-chronic-obstructive-pulmonary-disease-copd-pipeline-review-h2-2016.html . Companies discussed in this Chronic Obstructive Pulmonary Disease (COPD) Pipeline Review, H2 2016 report include AB2 Bio Ltd., Abeona Therapeutics, Inc., Ache Laboratorios Farmaceuticos S/A, Achillion Pharmaceuticals, Inc., Adamis Pharmaceuticals Corporation, Advinus Therapeutics Ltd, AlgiPharma AS, Allinky Biopharma, Alteogen Inc., Amakem NV, Ampio Pharmaceuticals, Inc., Angion Biomedica Corp., Apellis Pharmaceuticals Inc, Aridis Pharmaceuticals LLC, Astellas Pharma Inc., AstraZeneca Plc, Asubio Pharma Co., Ltd., Axikin Pharmaceuticals, Inc., Bayer AG, Beech Tree Labs, Inc., Bioneer Corporation, Biotie Therapies Corp., Boehringer Ingelheim GmbH, C4X Discovery Holdings PLC, Carolus Therapeutics, Inc., Cellular Biomedicine Group, Inc., Chiesi Farmaceutici SpA, Circassia Pharmaceuticals Plc, CSL Limited, Cytokinetics, Inc., Daiichi Sankyo Company, Limited, Diffusion Pharmaceuticals Inc., Domainex Limited, Elsalys Biotech SAS, enGene, Inc, Errant Gene Therapeutics, LLC, F. Hoffmann-La Roche Ltd., Foresee Pharmaceuticals, LLC, Galapagos NV, Gilead Sciences, Inc., GlaxoSmithKline Plc, Hanmi Pharmaceuticals, Co. Ltd., iCeutica, Inc., InMed Pharmaceuticals Inc., Innate Pharma S.A., INVENT Pharmaceuticals, Inc., Invion Limited, Jiangsu Hansoh Pharmaceutical Co., Ltd., Johnson & Johnson, KaloBios Pharmaceuticals, Inc., Kissei Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Ligand Pharmaceuticals, Inc., Medestea Research & Production S.p.A., Merck & Co., Inc., Mereo Biopharma Group Plc, Meridigen Biotech Co., Ltd., Microbion Corporation, Novartis AG, Odan Laboratories Ltd., OPKO Health, Inc., Orion Oyj, Panmira Pharmaceuticals, LLC., Pfizer Inc., PharmaLundensis AB, Pharmaxis Limited, Pila Pharma AB, Polyphor Ltd., Promedior, Inc., ProMetic Life Sciences Inc., Proteostasis Therapeutics, Inc., Pulmagen Therapeutics LLP, Pulmatrix, Inc., Quark Pharmaceuticals, Inc., Re-Pharm Limited, Recipharm AB, Respira Therapeutics Inc, Respiratorius AB, rEVO Biologics, Inc., Rhizen Pharmaceuticals S.A., SATT North SAS, Selvita S.A., Seoul Pharma Co., Ltd., Spring Bank Pharmaceuticals, Inc., Stelic Institute & Co., Inc., sterna biologicals Gmbh & Co KG, Sucampo Pharmaceuticals, Inc., Sun Pharma Advanced Research Company Ltd., Sunovion Pharmaceuticals Inc., Synovo GmbH, Syntrix Biosystems, Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., TGV-Laboratories, Therabron Therapeutics, Inc., Theravance Biopharma, Inc., Torrent Pharmaceuticals Limited, U.S. Stem Cell, Inc., Unizyme Laboratories A/S, Vectura Group Plc, Verona Pharma Plc, Vertex Pharmaceuticals Incorporated, Yuhan Corporation, Yungjin Pharm. Co., Ltd. and Zambon Company S.p.A. The Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 1, 13, 40, 29, 81, 25 and 5 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 3 molecules, respectively for Chronic Obstructive Pulmonary Disease (COPD). Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. Connect With Us on:
Blundell C.D.,C4X Discovery |
Packer M.J.,Astrazeneca |
Almond A.,C4X Discovery |
Almond A.,University of Manchester
Bioorganic and Medicinal Chemistry | Year: 2013
Accurate unbound solution 3D-structures of ligands provide unique opportunities for medicinal chemistry and, in particular, a context to understand binding thermodynamics and kinetics. Previous methods of deriving these 3D-structures have had neither the accuracy nor resolution needed for drug design and have not yet realized their potential. Here, we describe and apply a NMR methodology to the aminoglycoside streptomycin that can accurately quantify accessible 3D-space and rank the occupancy of observed conformers to a resolution that enables medicinal chemistry understanding and design. Importantly, it is based upon conventional small molecule NMR techniques and can be performed in physiologically-relevant solvents. The methodology uses multiple datasets, an order of magnitude more experimental data than previous NMR approaches and a dynamic model during refinement, is independent of computational chemistry and avoids the problem of virtual conformations. The refined set of solution 3D-shapes for streptomycin can be grouped into two major families, of which the most populated is almost identical to the 30S ribosomal subunit bioactive shape. We therefore propose that accurate unbound ligand solution conformations may, in some cases, provide a subsidiary route to bioactive shape without crystallography. This experimental technique opens up new opportunities for drug design and more so when complemented with protein co-crystal structures, SAR data and pharmacophore modeling. © 2013 Elsevier Ltd. All rights reserved.
Blundell C.D.,C4X Discovery |
Nowak T.,C4X Discovery |
Watson M.J.,C4X Discovery
Progress in Medicinal Chemistry | Year: 2015
Understanding the conformational behaviour of small molecules in free solution and its relationship to biological activity is of fundamental importance to drug discovery. How the free ligand's conformational envelope changes upon binding to its target to adopt the bound (bioactive) conformational envelope vitally impacts on the observed binding affinity. Minimisation of this change is crucial for optimal potency and therefore not only conformational analysis but also understanding of the molecular drivers that control conformational preferences are both required if drug ligands are to be rationally and intentionally designed. Until recently, however, comprehensive experimental measurement of the conformations that a free ligand adopts in solution conditions (its dynamic 3D structure) has not been possible. Techniques for the measurement of free ligand conformations are discussed, including a progressive and recently reported solution NMR method. The chief factors that affect ligand conformation are presented, providing a conformational design toolbox for the medicinal chemist. These two streams are combined to present a framework through which conformational design can be practised. Conformational design is a new emergent tool for the practising medicinal chemist that promises fresh insight, control and productivity in drug discovery. © 2016 Elsevier B.V.
Agency: GTR | Branch: Innovate UK | Program: | Phase: Feasibility Study | Award Amount: 148.29K | Year: 2014
Type-2 diabetes has assumed almost epidemic proportions, resulting in a significant financial burden to healthcare systems in developed countries. GLP-1R agonism represents one of the mainstays of therapy for type-2 diabetes, but existing GLP-1 mimetics necessitate injection and have been associated with severe side effects. Through the use of its proprietary NMR-based approach to drug design, C4X Discovery (C4X) has built the first comprehensive pharmacophore GLP-1R agonist map and used this to derive the smallest orthosteric agonist of GLP-1R so far reported. As part of the project, C4X will explore whether this molecule can form the basis of a chemical optimisation programme that will enable the creation of orally-available and cheaper alternatives to exisiting therapies, thereby providing a significant healthcare benefit in terms of increased patient convenience, improved compliance and reduced economic burden.
Agency: GTR | Branch: Innovate UK | Program: | Phase: Smart - Proof of Concept | Award Amount: 59.95K | Year: 2015
Type-2 diabetes (T2D) affects over 340 million people worldwide, creating an enormous healthcare and socio-economic burden. The GPR142 receptor has been recently suggested as a potential new target for treating T2D with a key advantage: its activation results in insulin secretion as desired but, unlike other targets, it does this only in the presence of high blood sugar levels. Medicines that work through GPR142 should therefore provide marked health benefits over existing T2D therapies, as they will avoid the life-threatening side effect of low blood sugar levels. Moreover, GPR142-based medicines would be orally administered, avoiding the problems caused by injection-based therapies. Poor patient complaince with injectables results in many of the T2D disease symptoms and most of the healthcare and financial burden on the NHS. GPR142-based medicines, if feasible, would therefore not only substantially improve T2D sufferers’ health but also reduce the cost burden on the NHS too. This project aims to carry out vital studies to confirm if GPR142 is indeed the exciting new target for T2D that it promises to be. Very encouraging preliminary literature reports show beneficial effects in clinically relevant acute animal models but, because T2D is a chronic disease, further validation work to assess the chronic effects of GPR142 control is vital to see if it is suitable for safe, long term control. The aim of this project is to perform chronic target validation studies and, if positive, thereby open up a new and better class of T2D medications. If positive, C4X has a head-start in leading this new area, having already designed hit molecules for GPR142 with excellent properties. Positive results would justify a subsequent C4X drug development programme. In time, this would lead to the creation of a new, convenient, safe and effective class of T2D medicines that would have an enormous positive impact on long-term patient health and the economic burden associated with T2D.
Agency: GTR | Branch: Innovate UK | Program: | Phase: Collaborative Research & Development | Award Amount: 139.64K | Year: 2017
Type-2 diabetes (T2D) affects over 420 million people worldwide, creating an enormous healthcare and socio-economic burden. The GPR142 receptor has been recently reported to be an exciting new target for the treatment of T2D with several advantages. Firstly, its activation results in insulin secretion but only in the presence of high blood sugar levels, avoiding the life-threatening side effect of low blood sugar associated with insulin-based therapies. Secondly, GPR142-based medicines would be orally administered, avoiding compliance issues caused by injectable therapies. Additionally, activating GPR142 leads to the release of GLP-1 - a clinically validated mechanism for the treatment of T2D. By applying its proprietary NMR-based approach to drug discovery, C4X Discovery has identified hit molecules for GPR142. This project is scoped to characterise and develop these hits to enable a chemical optimisation programme aiming to ultimately lead to a new, convenient, safe and effective class of T2D medicine that would have an enormous positive impact on long-term patient health and reduce the economic burden associated with the disease.
News Article | March 9, 2015
Dotmatics' platform to support internal and external collaborative research at C4X Discovery Dotmatics, the leading provider of scientific informatics solutions and services, announced today that after an exhaustive evaluation process, C4X Discovery has selected the Dotmatics Platform for its scientific data management and collaboration hub. C4X Discovery is focused on improving the efficiency and productivity of drug discovery and design through the use of NMR-based technology. The implementation of the Dotmatics Platform will facilitate their assay and 'meta' data management and analysis. C4X Discovery uses NMR to determine the dynamic 3D-conformations of biologically relevant molecules in solution. This simplifies rational drug discovery by complementing protein structure elucidation and/or computational chemistry workflows. C4X Discovery will use the Dotmatics Platform to store, analyse and manage its chemical and biology data. Register will be used to record samples and associated information while Studies will be the main hub for assay design, capture, validation and analysis. The powerful combination of web-based tools Browser and Vortex will be used to rapidly access information in real time, find trends and thus make real time decisions. The easy accessibility and high security of Dotmatics' cloud-based solutions provides C4X Discovery with a collaborative environment in which to share information internally, as well as with external partners from Academia and other Pharmaceutical and Biotech organisations. "We look forward to working with Dotmatics. Their informatics solutions significantly enhance our ability to maximise the value of our technology platform and our portfolio," said Piers Morgan, CEO of C4X Discovery. "C4X Discovery has a very interesting and novel approach to rational drug discovery and we are delighted to provide the informatics infrastructure to support their research," said Dr Stephen Gallagher, CEO of Dotmatics. "This deployment is testimony to the ability of our Platform to adapt to different workflows and deliver immediate value to our customers." Dotmatics is a leading global scientific informatics software and services provider, delivering solutions tailored to the modern, highly collaborative and mobile scientific environments. The company provides solutions to several vertical markets, including the pharmaceutical, biotechnology, academia, food and beverage, oil and gas and agrochemical industries. Dotmatics' enterprise solutions are flexible, scalable and configurable, providing effective scientific information management across entire organisations, from discovery research to development and early manufacturing. Dotmatics has significant expertise in scientific informatics, including database management for chemistry and biologics, electronic laboratory notebooks, chemical and biological registration, screening data management, SAR analysis, reporting, and visualisation. Dotmatics solutions are available for local or cloud deployment and they are supported on Microsoft Windows, Mac OS X and Linux. A privately owned company, Dotmatics was founded in 2005 and their headquarters is based south of Cambridge in the UK. C4XD is a Manchester-based company focused on optimising drug discovery and design. It was founded in 2008 as a spin-out from the University of Manchester. The company uses its NMR-based technology to solve the dynamic 3D structures of a broad range of biomolecules, including peptides, cofactors, oligonucleotides and carbohydrates. Since C4XD's NMR technology shows what shapes active molecules prefer to adopt, it provides high-quality templates for drug discovery and design, and valuable information for drug candidate optimisation. In addition, the data is generated faster and more reliably than standard techniques such as X-ray co-crystallography or molecular modelling. C4XD is using its technology in collaboration with the pharmaceutical industry and to build its own proprietary pipeline of high-value therapeutic candidates. For additional information please go to http://www.c4xdiscovery.com